Pavel Nockel1, Corina Millo2, Xavier Keutgen1, Joanna Klubo-Gwiezdzinska3, Jasmine Shell1, Dhaval Patel1, Naris Nilubol1, Peter Herscovitch2, Samira M Sadowski4, Electron Kebebew1. 1. 1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland. 2. 2 PET Department, Clinical Center, National Institutes of Health , Bethesda, Maryland. 3. 3 Diabetes, Obesity, and Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, Maryland. 4. 4 Thoracic and Endocrine Surgery, University Hospitals of Geneva , Geneva, Switzerland .
Abstract
BACKGROUND: Gallium-68 (Ga-68) DOTATATE is a radiolabeled peptide-imaging modality that targets the somatostatin receptor (SSTR), especially subtype 2 (SSTR2). Benign and malignant thyroid tumors have been observed to express SSTR. The aim of this study was to evaluate the frequency and clinical significance of incidental atypical thyroid uptake as detected by Ga-68 DOTATATE positron emission tomography/computed tomography (PET/CT). METHODS: A retrospective analysis was conducted of a prospective study in which 237 patients underwent Ga-68 DOTATATE PET/CT as part of a work-up for metastatic and unknown primary neuroendocrine tumors. The types of uptake in the thyroid gland (focal/diffuse) and maximum standardized uptake value (SUVmax) levels were evaluated and compared with the background uptake in the liver and salivary glands. RESULTS: Of 237 patients, 26 (11%) had atypical thyroid uptake as detected by Ga-68 DOTATATE PET/CT. There were no significant clinical or biochemical variables associated with atypical thyroid uptake. Fourteen (54%) patients had positive focal uptake, and 12 (46%) patients had diffuse uptake. Of the 14 patients with atypical focal uptake, 10 (71%) had thyroid nodules on the corresponding side, as detected by anatomic imaging. Three of 10 patients (21%) were found to have papillary thyroid cancer, and seven (70%) had adenomatoid nodules. Of the 12 patients with diffuse increased uptake, six (50%) had a history of hypothyroidism, five (42%) had chronic lymphocytic thyroiditis, and one (8%) had nontoxic multinodular goiter. CONCLUSIONS: Patients with an incidental focal abnormal thyroid uptake on Ga-68 DOTATATE PET/CT scan should have further clinical evaluation to exclude a diagnosis of thyroid cancer.
BACKGROUND:Gallium-68 (Ga-68) DOTATATE is a radiolabeled peptide-imaging modality that targets the somatostatin receptor (SSTR), especially subtype 2 (SSTR2). Benign and malignant thyroid tumors have been observed to express SSTR. The aim of this study was to evaluate the frequency and clinical significance of incidental atypical thyroid uptake as detected by Ga-68 DOTATATE positron emission tomography/computed tomography (PET/CT). METHODS: A retrospective analysis was conducted of a prospective study in which 237 patients underwent Ga-68 DOTATATE PET/CT as part of a work-up for metastatic and unknown primary neuroendocrine tumors. The types of uptake in the thyroid gland (focal/diffuse) and maximum standardized uptake value (SUVmax) levels were evaluated and compared with the background uptake in the liver and salivary glands. RESULTS: Of 237 patients, 26 (11%) had atypical thyroid uptake as detected by Ga-68 DOTATATE PET/CT. There were no significant clinical or biochemical variables associated with atypical thyroid uptake. Fourteen (54%) patients had positive focal uptake, and 12 (46%) patients had diffuse uptake. Of the 14 patients with atypical focal uptake, 10 (71%) had thyroid nodules on the corresponding side, as detected by anatomic imaging. Three of 10 patients (21%) were found to have papillary thyroid cancer, and seven (70%) had adenomatoid nodules. Of the 12 patients with diffuse increased uptake, six (50%) had a history of hypothyroidism, five (42%) had chronic lymphocytic thyroiditis, and one (8%) had nontoxic multinodular goiter. CONCLUSIONS:Patients with an incidental focal abnormal thyroid uptake on Ga-68 DOTATATE PET/CT scan should have further clinical evaluation to exclude a diagnosis of thyroid cancer.
Authors: Zeynep G Ozkan; Serkan Kuyumcu; Ayse Kubat Uzum; Mehmet F Gecer; Sevda Ozel; Ferihan Aral; Isik Adalet Journal: Nucl Med Commun Date: 2015-03 Impact factor: 1.690
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544
Authors: Samira M Sadowski; Corina Millo; Candice Cottle-Delisle; Roxanne Merkel; Lily A Yang; Peter Herscovitch; Karel Pacak; William F Simonds; Stephen J Marx; Electron Kebebew Journal: J Am Coll Surg Date: 2015-04-20 Impact factor: 6.113
Authors: Helen Atkinson; James A England; Amy Rafferty; Vim Jesudason; Karen Bedford; Laszlo Karsai; Stephen L Atkin Journal: Int J Exp Pathol Date: 2013-06 Impact factor: 1.925
Authors: Sriram Gubbi; Mohammad Al-Jundi; Jaydira Del Rivero; Abhishek Jha; Marianne Knue; Joy Zou; Baris Turkbey; Jorge Amilcar Carrasquillo; Emily Lin; Karel Pacak; Joanna Klubo-Gwiezdzinska; Frank I-Kai Lin Journal: Front Endocrinol (Lausanne) Date: 2021-01-21 Impact factor: 5.555
Authors: Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Sara Sheikhbahaei; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe Journal: Ann Nucl Med Date: 2018-08-14 Impact factor: 2.668